Publications

Find out some of the most recentpublications from our group

Colon


Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling

Nat Med. 2026 Jun 25
doi: 10.1038/s41591-026-04481-9


Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 – PRODIGE 107 – FFCD 2306 – COLOSOTO trial

Dig Liver Dis. 2026 Jul;58(7):966-972.
doi: 10.1016/j.dld.2026.04.009.


Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study

J Clin Oncol. 2026 Feb 10;44(5):361-369.
doi: 10.1200/JCO-25-01337.


Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials

J Clin Oncol. 2025 Sep 4;43(29):3184–3197.
doi: 10.1200/JCO-25-01003


Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO

Ann Oncol. 2026 Jan;37(1):79-91.
doi: 10.1016/j.annonc.2025.10.002.


Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer

J Clin Oncol. 2026 Jan;44(1):31-41.
doi: 10.1200/JCO-25-00596.


FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials

Eur J Cancer. 2025 Aug 15:228:115713.
DOI: 10.1016/j.ejca.2025.115713 – PMID: 40865392


Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments – analysis of eleven trials by AIO and GONO

Ann Oncol. 2025 Aug 19:S0923-7534(25)00921-4.
DOI: 10.1016/j.annonc.2025.08.001 – PMID: 40840710

Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancer

Nat Med. 2025 Jul;31(7):2416-2429.
DOI: 10.1038/s41591-025-03693-9 – PMID: 40461820

The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies.

Eur J Cancer. 2025 Jun 3:222:115470.
DOI: 10.1016/j.ejca.2025.115470 – PMID: 40306121

Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer

JCO Precis Oncol. 2025 Apr:9:e2400567.
DOI: 10.1200/PO-24-00567 – PMID: 40249885

Impact of the ONCOBIOME network in cancer microbiome research

Nat Med. 2025 Apr;31(4):1085-1098.
DOI: 10.1038/s41591-025-03608-8 – PMID: 40217075

Surrogate markers of intestinal dysfunction associated with survival in advanced cancers

Oncoimmunology. 2025 Dec;14(1):2484880.
DOI: 10.1080/2162402X.2025.2484880 – PMID: 40189749

Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study

ESMO Open. 2025 Feb;10(2):104135.
DOI: 10.1016/j.esmoop.2025.104135. – PMID: 39908699

A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer

Cancer Cell . 2025 Feb 10;43(2):292-307.e7.
DOI: 10.1016/j.ccell.2024.12.008 – PMID: 39824178

Prognostic impact of depth of response and early tumour shrinkage in patients with BRAF V600E -mutated metastatic colorectal cancer treated with targeted therapy

Ther Adv Med Oncol. 2025 Jan 7:17:17588359241299975.
DOI: 10.1177/17588359241299975 – PMID: 39776534

Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

JCO Clin Cancer Inform. 2024 Jul:8:e2400037.
doi: 10.1200/CCI.24.00037. – PMID: 39018510

KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration

JCO Precis Oncol. 2024 Nov;8:e2400329.
doi: 10.1200/PO.24.00329. Epub 2024 Nov 7. – PMID: 39509668.

Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study

J Clin Oncol. 2024 Jun 12:JCO2302728
doi: 10.1200/JCO.23.02728 – PubMed ID: 38865678

Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome

Cell. 2024 Jun 20;187(13):3373-3389.e16
doi: 10.1016/j.cell.2024.05.029 – PubMed ID: 38906102

Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial

Front Oncol. 2024 Feb 9:13:1307545
doi: 10.3389/fonc.2023.1307545 – PubMed ID: 38406172

Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies

Cancers (Basel). 2023 Nov 16;15(22):5451
doi: 10.3390/cancers15225451 – PubMed ID: 38001711

Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV

Eur J Cancer. 2023 Dec;195:113396
doi: 10.1016/j.ejca.2023.113396 – PubMed ID: 37924647

Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies

Cancers (Basel). 2023 Nov 16;15(22):5451
doi: 10.3390/cancers15225451 – PubMed ID: 38001711 – PMCID: PMC10670103

The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study

Future Oncol – 2023 Jul
doi: 10.2217/fon-2023-0406 – PubMed ID: 37577810

Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by GONO Foundation

J Clin Oncol. 2023 Aug 3
doi: 10.1200/JCO.23.00506 – PubMed ID: 37535876

ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer

Clin Colorectal Cancer. 2023 Jun 11
doi: 10.1016/j.clcc.2023.06.002 – PubMed ID: 37429749

Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials

Eur J Cancer. 2023 Aug;
doi: 10.1016/j.ejca.2023.05.001 – PubMed ID: 37301718

An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer

Clin Cancer Res. 2023 Jun 13
doi: 10.1158/1078-0432.CCR-22-3878 – PubMed ID: 37022350

Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study.

J Immunother Cancer. 2023 Apr
doi: 10.1136/jitc-2022-006633 – PubMed ID: 37085190

Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials

Cancer Med. 2023 Apr
doi: 10.1002/cam4.5699 – PubMed ID: 36880426

Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs’ development

Br J Cancer. 2023 Mar
doi: 10.1038/s41416-023-02180-7 – PubMed ID: 36759721

Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials Journal

ESMO Open – 2022
doi 10.1016/j.esmoop.2022.100606 – PubMed ID: 36327757

Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials Journal

European Journal of Cancer – 2022
doi 10.1016/j.ejca.2022.05.016 – PubMed ID: 35749909

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO

Journal of Clinical Oncology – 2022
doi 10.1200/JCO.22.00839 – PubMed ID: 35666229

Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?

British Journal of Cancer – 2022
doi 10.1038/s41416-022-01852-0 – PubMed ID: 35665778

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Lancet Oncol – 2022
doi 10.1016/S1470-2045(22)00274-1 – PubMed ID: 35636444

Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies

European Journal of Cancer – 2022
doi 10.1016/j.ejca.2022.04.019 – PubMed ID: 35594613

Encorafenib plus cetuximab treatment in BRAF V600E mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series

European Journal of Cancer – 2022
doi 10.1016/j.ejca.2022.03.011 – PubMed ID: 35436675

FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies

European Journal of Cancer – 2022
doi 10.1016/j.ejca.2022.02.031 – PubMed ID: 35366570

Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature

Cancer Treatment Reviews – 2022
doi 10.1016/j.ctrv.2021.102326 – PubMed ID: 35016085

Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO

ESMO Open – 2021
doi 10.1016/j.esmoop.2021.100293 – PubMed ID: 34689001

Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications

Journal of the National Cancer Institute – 2021
doi 10.1093/jnci/djab169 – PubMed ID: 34469533

Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study

European Journal of Cancer – 2021
doi 10.1016/j.ejca.2021.06.037 – PubMed ID: 34365081

Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients

Clinical Colorectal Cancer – 2021
doi 10.1016/j.clcc.2021.07.001 – PubMed ID: 34364814

Upper GI

Other pathologies

Empty section. Edit page to add content here.